Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular marker study to predict response to sorafenib and camrelizumab in advanced hepatocellular carcinoma
ChiCTR1900028222Phase 4Not yet recruiting
- Sponsor
- Second Hospital of Lanzhou University
- Start
- Jan 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sorafenib and camrelizumab in hepatocellular carcinoma (HCC) (3 arms), sponsored by Second Hospital of Lanzhou University. Primary endpoints: Disease-free survival, Overall survival and 2 more. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
sorafenibcamrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR1900028222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900028222.